Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.26355/eurrev_202111_27123 http://scihub22266oqcxt.onion/10.26355/eurrev_202111_27123 34787883!ä!34787883 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Rev+Med+Pharmacol+Sci 2021 ; 25 (21): 6782-6796 Nephropedia Template TP {{tp|p=34787883|t=2021. Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids |pdf=|usr=}}{{34787883}} gab.com Text Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids JO: Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34787883 #FOAvip OBJECTIVE: This study aimed to evaluate the eicosanoid and pro resolutive parameters in SARS COVID-19 patients with the severe acute respiratory syndrome. PATIENTS AND METHODS: Fourteen male patients with an acute respiratory syndrome caused by SARS COVID-19 and four healthy controls were evaluated by measuring the following parameters in plasma: Polyunsaturated fatty acids: EPA, DHA, ARA, and DPA. Specialized Pro-resolving mediators (SPMs) (including monohydroxy-containing precursors 17-HDHA, 18-HEPE, 14-HDHA) resolvins, maresins, protectins, and lipoxins. The eicosanoids group included prostaglandins, thromboxanes, and leukotrienes. RESULTS: Plasma from COVID-19 patients presented higher amounts of pro-inflammatory and pro-thrombotic lipid mediators as compared to healthy subjects (65.7 pg/ml vs. 10.2 pg/ml), including thromboxane (2142.6 pg/ml vs. 10.4 pg/ml), and the ratio between total plasma pro-inflammatory mediators versus total SPM's was 13.2 to 0,4, respectively. CONCLUSIONS: A clear disbalance favoring the pro-inflammatory axis is described, showing the need to perform future clinical interventions in these patients using SPM's or monohydroxylated lipid mediators derivates from fatty acids. Twit Text FOAVip Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids ????Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=34787883 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34787883 #FOAvip English Wikipedia <ref>{{Cite pmid|34787883}}</ref> Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids #MMPMID34787883 Regidor PA; De La Rosa X; Santos FG; Rizo JM; Gracia Banzo R; Silva RS Eur Rev Med Pharmacol Sci 2021[Nov]; 25 (21): 6782-6796 PMID34787883show ga OBJECTIVE: This study aimed to evaluate the eicosanoid and pro resolutive parameters in SARS COVID-19 patients with the severe acute respiratory syndrome. PATIENTS AND METHODS: Fourteen male patients with an acute respiratory syndrome caused by SARS COVID-19 and four healthy controls were evaluated by measuring the following parameters in plasma: Polyunsaturated fatty acids: EPA, DHA, ARA, and DPA. Specialized Pro-resolving mediators (SPMs) (including monohydroxy-containing precursors 17-HDHA, 18-HEPE, 14-HDHA) resolvins, maresins, protectins, and lipoxins. The eicosanoids group included prostaglandins, thromboxanes, and leukotrienes. RESULTS: Plasma from COVID-19 patients presented higher amounts of pro-inflammatory and pro-thrombotic lipid mediators as compared to healthy subjects (65.7 pg/ml vs. 10.2 pg/ml), including thromboxane (2142.6 pg/ml vs. 10.4 pg/ml), and the ratio between total plasma pro-inflammatory mediators versus total SPM's was 13.2 to 0,4, respectively. CONCLUSIONS: A clear disbalance favoring the pro-inflammatory axis is described, showing the need to perform future clinical interventions in these patients using SPM's or monohydroxylated lipid mediators derivates from fatty acids. |Acute Disease[MESH] |Adult[MESH] |COVID-19/*diagnosis/pathology/virology[MESH] |Case-Control Studies[MESH] |Chromatography, High Pressure Liquid[MESH] |Eicosanoids/*blood[MESH] |Fatty Acids, Unsaturated/blood[MESH] |Humans[MESH] |Inflammation Mediators/*blood[MESH] |Male[MESH] |SARS-CoV-2/isolation & purification[MESH] |Severity of Illness Index[MESH] |Tandem Mass Spectrometry[MESH]Acute severe SARS COVID-19 patients produce pro-resolving lipids media(epmc).pdf DeepDyve Pubget Overpricing